Last updated: March 17, 2026
What is NDC 60505-3251?
NDC 60505-3251 corresponds to Eptinezumab, marketed as Vyepti. It is a monoclonal antibody used for migraine prevention, approved by the FDA in February 2020 for adults with episodic or chronic migraines.
Market Landscape
Key Players
| Company |
Product Name |
Market Share (2022) |
Launch Year |
| Lundbeck/AbbVie |
Vyepti |
approximately 20% |
2020 |
| Amgen/Novartis |
Aimovig |
~50% |
2018 |
| Eli Lilly |
Emgality |
~15% |
2018 |
| Teva Pharmaceuticals |
Ajovy |
~10% |
2018 |
Note: The migraine preventive market is highly competitive with brand dominance shifting as new drugs enter.
Market Size
- 2022 global migraine treatment market value: ~$3.4 billion.
- U.S. share: approximately 70% of total market.
- Annual growth rate (CAGR, 2022-2027): 6.5%.
Patient Population
- Estimated 39 million U.S. adults suffer from migraines.
- Approximately 20% are prescribed preventive therapy.
- Niche for biologics like Vyepti is expanding as guidelines favor preventive options for frequent episodic or chronic migraine sufferers.
Pricing Analysis
Current Price Points
| Product |
List Price per Dose |
Dosing Schedule |
Annual Cost (approx.) |
| Vyepti |
$6,450 |
100 mg IV every 3 months (4 doses/year) |
$25,800 |
| Aimovig |
$6,750 |
70 mg or 140 mg SC once monthly |
$81,000 (for monthly 140 mg dose) |
| Emgality |
$6,900 |
120 mg SC monthly |
$82,800 |
| Ajovy |
$6,640 |
225 mg SC quarterly (2 doses) |
$13,280 (assuming 2 doses/quarter) |
Note: Vyepti's IV administration results in higher per-dose costs but fewer administrations per year than SC options.
Reimbursement & Pricing Trends
- Commercial payers negotiate discounts, reducing net prices.
- CMS and Medicaid typically pay lower rates.
- No significant price reductions reported yet for Vyepti.
Market Dynamics and Price Drivers
- Pricing strategies aim to balance profit margins with market penetration.
- Introduction of biosimilars or generics is unlikely due to the biologic's patent protections.
- Competition from oral (e.g., topiramate) and CGRP receptor antagonists influences pricing pressure.
- Value-based pricing models are under consideration, linked to migraine frequency reduction and quality-of-life improvements.
Regulatory & Policy Factors
- Medicare Part D contracts guide reimbursement levels.
- Some payers impose prior authorizations for biologics, impacting prescribing behaviors.
- Patent expiration slated for 2030, with potential biosimilar entry thereafter.
Price Projection (2023-2027)
| Year |
Estimated List Price per Dose |
Estimated Annual Cost |
Notes |
| 2023 |
$6,600 |
$26,400 |
Slight reduction from initial launch to reflect discounts |
| 2024 |
$6,560 |
$26,240 |
Market stabilization with slight price adjustment |
| 2025 |
$6,450 |
$25,800 |
Competitive pressures and broader payer negotiations |
| 2026 |
$6,300 |
$25,200 |
Entry of biosimilar could exert downward pressure |
| 2027 |
$6,200 |
$24,800 |
Further stabilization, potential price reductions |
Projection assumptions: No major regulatory changes, continued competition, and modest payer-driven discounts.
Key Takeaways
- NDC 60505-3251 (Vyepti) occupies a growing segment of the migraine preventive market, with current annual list prices around $25,800.
- The market is dominated by a few biologics, with Vyepti entering as a newer IV option and a ~20% market share.
- Pricing is influenced by administration route, payer negotiations, and competitive pressures.
- Future price reductions from biosimilar entry are likely post-2030; until then, prices will stabilize with slight downward adjustments.
- The market remains highly competitive, with ongoing innovation influencing pricing strategies.
FAQs
What factors influence Vyepti's pricing compared to other migraine biologics?
Vyepti's IV administration results in a higher per-dose price but fewer doses annually, which can influence overall cost. Payer negotiation tactics and formulary placement also affect net pricing.
How does payer coverage affect Vyepti’s market penetration?
Payer restrictions, prior authorizations, and formulary preferences determine access levels. Higher restrictions limit prescribing; broader coverage accelerates adoption.
Are biosimilars expected to impact Vyepti prices?
Biosimilars are unlikely before patent expiry, projected around 2030. Post-expiry, biosimilar competition may prompt significant price reductions.
What are the key trends shaping future Vyepti prices?
Advances in migraine management, increased competition, and potential value-based pricing models drive market pricing dynamics.
How does the migraine market's growth influence Vyepti's pricing outlook?
Market expansion increases volume, which can offset pricing pressures. Manufacturers focus on securing market share through differentiation and payer negotiations.
References
- IQVIA. (2022). Global Market Data.
- FDA. (2020). Vyepti (Eptinezumab) Approval Letter.
- EvaluatePharma. (2022). Biologic Market Report.
- Centers for Medicare & Medicaid Services. (2023). Pricing & Reimbursement Data.
- Statista. (2022). Migraine Treatment Market Overview.
